Commitments and Contingencies (Details) $ in Millions									1 Months Ended				6 Months Ended
	Apr. 16, 2025	Apr. 07, 2025 USD ($)	Aug. 27, 2024	Feb. 24, 2023	Feb. 15, 2023 litigationCase	Jul. 21, 2022	Jun. 22, 2022 litigationCase	Jun. 23, 2020 litigationCase	Mar. 31, 2023 patent	Feb. 28, 2023 patent	Jul. 31, 2021 patent	Jun. 30, 2021 patent	Jun. 30, 2025 USD ($)	Jun. 07, 2022 patent	May 31, 2021 patent	May 13, 2021 patent
Loss Contingencies [Line Items]
Settlement amount | $		$ 145.0
Litigation expense | $													$ 172.0
Teamsters and GEHA Lawsuits
Loss Contingencies [Line Items]
Number of lawsuits filed | litigationCase								2
Avadel Pharmaceuticals plc Lawsuit
Loss Contingencies [Line Items]
Infringed patents suit, number of patents															5
Infringed patents suit, other party counterclaim, number of patents requested to be delisted																1
Number of days provided to delist patent (in days)				14 days
Number of patents, paragraph IV certification notice filed														1
Royalty rate for future sale (as a percent)			3.50%
Number of days requested for FDA to take action (in days)						14 days
Lupin Lawsuit
Loss Contingencies [Line Items]
Number of lawsuits filed | litigationCase					2		2
Infringed patents suit, number of patents											10
Number of patents, paragraph IV certification notice filed												10
FDA stay of approval period (in months)											30 months
Lupin Lawsuit | Xywav
Loss Contingencies [Line Items]
FDA recognition of orphan drug exclusivity, period (in years)												7 years
Teva Lawsuit
Loss Contingencies [Line Items]
Infringed patents suit, number of patents									13
FDA stay of approval period (in months)									30 months
Infringed patents suit, number of patents										13
Defitelio Patent Litigation
Loss Contingencies [Line Items]
FDA stay of approval period (in months)	30 months